MK-677 and ipamorelin both raise growth hormone by activating the same ghrelin receptor. However, they differ in one immediately practical way. MK-677 is a small-molecule compound taken orally. Ipamorelin is a peptide that must be injected. MK-677 also carries a documented cardiovascular safety signal from its most rigorous human trial, which has no equivalent in the ipamorelin literature.
Ipamorelin vs MK-677 — key differences
Despite acting on the same receptor, ipamorelin and MK-677 (ibutamoren) are chemically very different types of compounds. This distinction explains most of their practical differences. Ipamorelin is a peptide, a chain of five amino acids. Therefore, it must be injected rather than swallowed. As discussed in earlier articles in this series, peptides of this kind are generally broken down by digestive enzymes before they can be absorbed intact from the intestine [1].
MK-677, by contrast, is a small, non-peptide molecule. This different chemical structure is precisely what allows it to survive digestion and be taken as an oral pill or capsule. This makes it fundamentally different from ipamorelin in terms of how it is actually used on a daily basis, even though both activate the same ghrelin receptor (GHS-R1a) to stimulate growth hormone release.
In terms of human safety data, these two compounds diverge significantly. It is worth taking this seriously, rather than as a minor footnote.
The most significant human clinical study of ipamorelin, a Phase 2 trial in patients recovering from bowel resection surgery, showed an adverse event rate no higher than that of placebo over a short, seven-day, medically supervised treatment period [2].
By contrast, the most rigorous human study of MK-677 was a Phase 2b trial in elderly patients recovering from a hip fracture. It raised a specific, noteworthy safety concern. Although MK-677 significantly increased IGF-1 levels compared to placebo, as intended, the study showed a higher rate of congestive heart failure in the treatment group—6.5% — compared to the placebo group—1.7%. The study’s own published conclusion described the drug’s safety profile in this population as unfavorable [3].
It is important to note that this signal emerged specifically in older patients with a hip fracture, a population with heightened baseline cardiovascular susceptibility, and its relevance to other populations remains debated. However, this is a true, documented finding with no direct counterpart in the literature for ipamorelin reviewed for this series.
Both compounds also share an important consideration. The primary mechanistic profile of ipamorelin stimulates appetite via the ghrelin pathway, which is relevant for anyone using either compound with weight management goals. Neither has completed the regulatory approval process required for general human use in any country.
| Feature | Ipamorelin | MK-677 (Ibutamoren) |
|---|---|---|
| Chemical class | Peptide (pentapeptide) [4] | Non-peptide small molecule |
| Application route | Injection (intravenous in clinical trials) [2] | Oral (tablet/capsule) |
| Mechanism | Ghrelin receptor agonist (GHS-R1a) [4] | Ghrelin receptor agonist (GHS-R1a) |
| Regulatory status | FDA unapproved | FDA unapproved |
| A noteworthy human study | Phase 2 study of paralytic ileus; non-elevated adverse events vs. placebo [2] | Phase 2b trial of hip fractures; terminated early due to a CHF signal (6.51 TP30T vs. 1.71 TP30T for placebo) [3] |
| Effect on cortisol/prolactin | It does not raise any of them significantly, even at high doses [4] | It was not a synthesis of available research data |
| WADA ban status | Yes (category S2) | Yes |
Ipamorelin vs GHRP-2 and GHRP-6
Within the broader family of ghrelin receptor agonists, the original foundational research on ipamorelin directly compared it to GHRP-2 and GHRP-6. This comparison is where ipamorelin's defining characteristic becomes clear. These studies showed that all three compounds stimulated growth hormone release with generally comparable potency in animal tests. GHRP-6 and GHRP-2 both, however, significantly elevated ACTH and cortisol, whereas ipamorelina did not, even at doses over 200 times higher than needed for its growth hormone-releasing effect [4].
This selectivity is a primary, well-documented reason why ipamorelin is generally regarded in the scientific literature as a more sophisticated compound than those earlier, older-generation GHRPs. Avoiding the unwanted stress hormone response alongside the intended growth hormone effect is considered pharmacologically beneficial.
Hexarelin, a related and more potent hexapeptide in the same GHRP family, illustrates this trade-off even more clearly. Peer-reviewed human studies have repeatedly documented that hexarelin produces a stronger acute growth hormone stimulation than many other GHRPs. However, this is accompanied by a well-established, significantly greater increase in ACTH and cortisol. This effect has been studied specifically for its clinical relevance and has been shown to vary with age [5].
This pattern in the GHRP family, where greater potency in some compounds (hexarelin, GHRP-2, GHRP-6) tends to be accompanied by a greater unwanted cortisol response, while ipamorelin trades some peak potency for markedly better selectivity, is one of the most consistent and well-supported findings in this entire area of research.
Ipamorelin vs HGH, IGF-1 LR3 and AOD-9604
Direct human growth hormone (HGH) and ipamorelin work through fundamentally different approaches, even though both ultimately raise growth hormone activity in the body. HGH delivers a steady, external dose of the hormone directly. Ipamorelin stimulates the body's own pituitary gland to release its own growth hormone, triggering a single, independent pulse peaking about 40 minutes after administration, which then subsides within a few hours [1]. No published study has directly compared ipamorelin with HGH for any specific outcome. Declaring one better than the other is therefore not supported by current evidence, although the difference in approach—external hormone versus stimulated independent production—is well-documented and significant.
IGF-1 LR3 represents yet another distinct approach. Instead of stimulating growth hormone release like ipamorelin, it is a modified, longer-acting form of IGF-1 itself, acting further down the chain than the site of ipamorelin's action. No studies directly comparing the two compounds were identified in this series.
AOD-9604, discussed in more detail in the CJC-1295 comparison articles in this series, is a growth hormone fragment, amino acids 176–191, specifically developed to isolate fat-metabolizing properties while minimizing broader effects on the growth hormone axis. It has undergone a significantly more extensive human clinical research history than ipamorelin, including multiple phase 2 obesity trials, although a pivotal trial failed to replicate its earlier weight loss findings [6].
No study has directly compared AOD-9604 and ipamorelin. Given ipamorelin's own animal data suggesting a potential fat gain rather than fat loss effect, discussed in earlier articles in this series, these two compounds are not interchangeable for weight-related purposes based on current evidence.
Limitations of current evidence
The lack of cortisol/prolactin elevation by ipamorelin is well documented by its basic pharmacological studies [4]. This selectivity advantage over hexarelin, GHRP-2, and GHRP-6 is consistently supported in numerous peer-reviewed human studies [4], [5].
The cardiovascular safety signal of MK-677 from its hip fracture study is a real, published finding, although its relevance outside of this specific older, high-risk population remains an open question [3].
No published studies directly compare ipamorelin to HGH, IGF-1 LR3, or AOD-9604 in a human comparative study. Therefore, all comparisons in this article describe the separate evidentiary base of each compound rather than confirmed relative potency.
Disclaimer
Ipamorelin, MK-677, hexarelin, GHRP-2, GHRP-6, and AOD-9604 are not approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body for any general therapeutic or performance-related human use. None of these compounds are manufactured or sold under the quality and safety oversight that applies to approved pharmaceuticals. The information in this article is based on published clinical trial and pharmacological research data and does not establish that any of these compounds are safe or effective for general use. This article is provided for general educational and informational purposes only, reflects the state of published scientific literature at the time of writing, and does not constitute medical advice. Nothing in this article should be used to select, combine, or self-administer any of these compounds.
References
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[3] Adunsky, A., Chandler, J., Heyden, N., Lutkiewicz, J., Scott, B. B., Berd, Y., Liu, N., & Papanicolaou, D. A. (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics, 53(2), 183–189. https://doi.org/10.1016/j.archger.2010.10.004
[4] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
[5] Arvat, E., Ramunni, J., Bellone, J., Di Vito, L., Baffoni, C., Broglio, F., Deghenghi, R., Bartolotta, E., & Ghigo, E. (1997). The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations. European Journal of Endocrinology, 137(6), 635–642. https://doi.org/10.1530/eje.0.1370635
[6] Wittert, G. A., Hunter, C. E., Zsombor-Murray, E., et al. (2005). AOD9604, an orally active peptide for the treatment of obesity: Results of a phase 2b study. Diabetes, 54(Suppl. 1), A101.